Scitex Continuous Tone or Scitex CT is an image file format. It is designed specifically for use on Scitex graphics processing equipment. Its use is supported by numerous graphics suites and desktop publishing packages, such as Adobe Photoshop, Adobe InDesign, and QuarkXPress. Wikipedia.

Time filter
Source Type

News Article | April 26, 2017

JERUSALEM (Reuters) - Teva Pharmaceutical Industries' finance chief Eyal Desheh will step down in the next few months after nearly a decade in the job, the second top official to resign from the Israel-based company this year. "Yesterday, I celebrated my 65th birthday and I'm transitioning into the next phase of my career," Desheh said on Wednesday, without elaborating. Israeli media reported on Tuesday that Desheh is likely to be appointed as chairman of Isracard, the credit card unit of Bank Hapoalim, the country's largest bank, which said there were a number of candidates. Teva said it would immediately start a search for a new CFO, but that Desheh will take part in the company's first-quarter earnings call on May 11. Teva was left without a permanent chief executive in February after Erez Vigodman stepped down, leaving new management to restore confidence in the world's biggest generic drugmaker after a series of missteps. A string of costly acquisitions, along with delayed drug launches, have sent Teva shares plummeting and led to calls for management and structural changes, including a possible split into separate generic and branded medicine units. That forced former Vigodman to step down, with Chairman Yitzhak Peterburg replacing him on a temporary basis and Sol Barer taking the reins as chairman. "My highest priority is to identify and appoint Teva's next chief executive officer," Barer said. "We expect the company’s new CEO to have a significant role in identifying Eyal’s successor." Desheh served as deputy CFO from 1989 to 1996 before becoming CFO of Scitex and then Check Point Software Technologies. He returned as Teva's CFO in 2008 and was acting CEO from October 2013 to February 2014. Investors say Teva, which faces pricing pressure in its core generics business and faces competition on its key branded drug Copaxone for multiple sclerosis, must choose a new CEO with extensive pharmaceutical experience.

News Article | May 24, 2017

CHICAGO, IL--(Marketwired - May 24, 2017) - Cushing, a creative print and display graphics firm, today announced their office relocation to 213 West Institute Place, in the River North area of Chicago. Approximately one-half mile from their previous location at 420 West Huron Street, Cushing has called the River North area home for over thirty years. Doors open in the new shop on Monday, June 5. There are several benefits to the office move. Production consolidates from two floors to one, to occupy approximately half of the office space, with all graphic services fulfilled in a central shop. Clear of obstructions, the open concept encourages team communication, improves workflow, and project turn times. Administrative departments including accounting, business development, and marketing are set to occupy the other half of the floor plan. Customers do not have to travel far for projects or reach staff members: 213 West Institute is convenient to all of Chicagoland, with access to public transportation, major interstates, and two downtown Metra stations. "We spent several months, contemplating many factors of this move and thrilled to stay downtown and be part of the continued growth in River North, it's an integral part of our brand," said Joseph X. Cushing, Executive Vice President at Cushing. "We look forward to seeing clients, old and new, in the shop and around the neighborhood." Buildout at 213 West Institute Place began in November of 2016 and the Cushing team is set to occupy the entire second floor. As part of the move, Cushing has invested in a new HP Scitex FB750 flatbed press to improve the customer experience. Part of an ongoing education lunch and learn series, Cushing welcomes brand and marketing expert James Ellis to present on employer brand marketing on Wednesday, June 21. During the two-day move, the shop floor is open and projects are being completed. Phone and email contact information stays the same and below is the physical address: Should you have any questions or need to reach a member of the Cushing team, call: 312.266.8228. For questions related to a project: Customers that need to reach the team for pricing should email: Additional information about the move can be found online: About Cushing When print comes to shove, trust your Cushing team to go the extra mile. From wide format display graphics to short run projects, we are your one-stop solutions provider. Reaching beyond Chicago? Connect with over 250 print professionals through an expanding ReproMAX network. Browse our website for a growing list of custom printing services & meet the faces behind the fonts.

Challinger P.R.,Scitex
31st SMPTE Advanced Motion Imaging Conference Technical Papers Program | Year: 2015

There have been various disputes in the past over the relative merits of proprietary hardware versus software only running on standard platforms for post production editing. This paper looks at the strengths of both sides, how these can be merged most effectively and why video effects specific hardware is required for cost effective high performance systems. Some examples of the historical development of effects in editing are given and the trade-offs that occurred in effects capability when nonlinear editors first appeared are discussed. These issues are examined in the context of the merger of two companies and the combination of the respective technologies to create a nonlinear editing system with real-Time high-end effects capability. © 1997 Society of Motion Picture and Television Engineers, Inc.

News Article | December 6, 2016

HINGHAM, Mass., Dec. 06, 2016 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq:MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today announced that Mr. Hezi Himelfarb has been appointed General Manager and Chief Operating Officer, effective immediately.  In his position, Mr. Himelfarb will report directly to Harel Gadot, Microbot Medical’s Chairman, President and Chief Executive Officer. Mr. Himelfarb will manage the Company’s day-to-day operating activities and his responsibilities include overseeing product development, clinical programs, regulatory affairs and commercialization preparation. Mr. Himelfarb joins Microbot after serving since 2008 as the Chief Executive Officer of IceCure-Medical Ltd., a Tel Aviv Stock Exchange (TASE) listed company focused on advanced cryotherapy systems intended for the growing physician-office market. From 1999 to 2008, he was the Chief Executive Officer of Remon Medical Technologies Ltd., a developer of smart, miniature implants enabling physicians to assess and treat a variety of medical conditions, which was acquired in 2008 by Boston Scientific Corporation.  Prior to Remon, he managed Medtronic InStent Israel, which he joined after spending 14 years at Scitex Corporation, where he held positions of increasing responsibility including research and development. Mr. Himelfarb holds a B.Sc. in Electronic Engineering and an MBA, both from Tel-Aviv University. “Hezi’s outstanding operational and leadership skills, as well as his experience in healthcare and the public capital market, strengthen our team’s core capabilities.  He is a proven leader who has successfully funded and helped guide products from initial development through the clinical and regulatory approval process and he has led successful M&A transactions.  I am looking forward to working with him to continue advancing our initial neuro and GI products from development phase to successful commercial launch,” commented Mr. Gadot. “Microbot Medical is addressing a serious unmet need afflicting millions of patients globally and I look forward to working with Harel and the rest of the leadership team to successfully complete our clinical development and then build the go-to-market strategy to provide physicians with our treatment solutions,” commented Mr. Himelfarb. Microbot Medical is a medical device company specializing in the design and development of transformational micro-robotic medical technologies.  The Company is primarily focused on leveraging its micro-robotic technologies with the goal of allowing more physicians to treat more patients while improving surgical outcomes for the patients. The Company is currently developing its first two product candidates: the Self Cleaning Shunt, or SCS, for the treatment of hydrocephalus and Normal Pressure Hydrocephalus, or NPH; and TipCAT, a self-propelling, semi-disposable endoscope that is being developed initially for use in colonoscopy procedures. Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the businesses of Microbot Medical, Inc. particularly those mentioned in the cautionary statements found in Microbot Medical Inc.’s filings with the Securities and Exchange Commission. Microbot Medical disclaims any intent or obligation to update these forward-looking statements.

Halevi E.,Scitex
International Paper Board Industry | Year: 2014

HP has a very structured development process and it starts with plotting the broad-based, high-level understanding and needs of the market. Customer involvement is based on on-going visits, covering market sectors and geographic regions as well as companies of various sizes. While the HP Scitex FB7600 Industrial Press successfully accelerated the migration from screen to digital, a solution was needed to offer the benefits of digital production to flexo and offset converters. Among the goals for the new press were enhanced color and tone variations, smoother transitions from light to dark and improved image quality for fine detail and small type sizes. About mid-way in the process, following the continuing individual meetings, customers are brought together. These are managers and owners from all over the world. This is either in a virtual room, or real one, and customers are given tasks and situations to make them prioritize their requirements.

Zhang X.,Purdue University | Veis A.,Scitex | Ulichney R.,Hewlett - Packard | Allebach J.P.,Purdue University
Proceedings - International Conference on Image Processing, ICIP | Year: 2012

Multilevel halftoning algorithms are becoming increasingly important as the capabilities of image output devices improve. The traditional approach to multilevel halftoning is hampered by the appearance of contouring in the vicinity of native tones of the output device. To overcome this limitation, we propose a novel framework based on maintaining a consistent periodic, clustered-dot halftone texture across the tone scale. We develop metrics for granularity and structure dissimilarity, and show how these can be used to guide the manner in which the halftone texture evolves from native tone to native tone, across the tone scale. Experimental results confirm the benefits of our new approach. © 2012 IEEE.

Tang C.,Purdue University | Veis A.,Scitex | Ulichney R.,Hewlett - Packard | Allebach J.,Purdue University
Proceedings of SPIE - The International Society for Optical Engineering | Year: 2014

With digital printing systems, the achievable screen angles and frequencies are limited by the finite addressability of the marking engine. In order for such screens to generate dot clusters in which each cluster is identical, the elements of the periodicity matrix must be integer-valued, when expressed in units of printer-addressable pixels. To achieve a better approximation to the screen sets used for commercial offset printing, irregular screens can be used. With an irregular screen, the elements of the periodicity matrix are rational numbers. In this paper, we describe a procedure for design of high-quality irregular screens. We start with the design of the midtone halftone pattern. We then propose an algorithm to determine how to add dots from midtone to shadow and how to remove dots from mid-tone to highlight. We present experimental results illustrating the quality of the halftones resulting from our design procedure by comparing images halftoned with irregular screens using our approach and a template-based approach. © 2014 SPIE-IS&T.

News Article | October 13, 2000

As news of the latest tensions in the region filtered through the corridors at the Etre conference, the Israeli entrepreneurs in attendance said they didn't expect any lasting fallout retarding the growth of their local technology market. "We're not talking about a country that has faced this kind of thing for the first time," said Eli Barkat, the chief executive of BackWeb. "I still say that the most dangerous thing you can do in Israel is to drive on the highways." Like many other companies founded by Israelis, BackWeb's marketing and sales headquarters are located in the United States, and thus the company is able to operate even in the midst of a major political flare-up. Still, Israelis, who are heavily represented at this conference, expressed caution in making any predictions. "In the short term, I expect that there will definitely be some effect," said Isaac Levanon, the chief executive of FlyOver Technologies Inc. "For instance, the Telecom 2000 conference is set for the beginning of November, and I wouldn't be surprised if there were some cancellations. "Also, you might see some effect if somebody was planning to fly to Israel on business and their spouse won't let them fly because of the situation," he added. To be sure, there are ripple effects. For instance, political tensions figured into Scitex Corp.'s recent decision to delay spinning out one of its units as a public company. Scitex President Yoav Chelouche said advisers counseled him to wait, suggesting that concern about the Middle East situation might dampen investor enthusiasm for Israeli initial public offerings. On Thursday, shares of Israeli technology companies got pounded on Wall Street. But the context for the sell-off was the general drubbing of the Dow and Nasdaq as worries about oil contributed to the general nervousness. Like fellow Israeli executives here, Ayala Rahav, the CEO of Homing Inc., said she was "horrified" by the pictures transmitted by television, but dismissed suggestions that the news would constitute a serious blow to Israeli startups. "For research and development purposes, Israel is one of the best places to be," she said. "The stock market reacts to immediate events. Something can be today's crisis and forgotten a month from now." During one of the breakout sessions at Etre, which concludes on Friday, Jon Medved, a senior partner with Israel Seed Partners, said the country is so awash with venture capital money that "someone would need to be brain dead not to get funded." But that was before the latest outbreak of violence. After watching the reports carried on CNN, Gali Idan, the sales manager of Koldoon, sounded a more restrained note. "It's really too early to say (whether there will be lasting effects on the Israeli high-tech market)," she said. "But if it doesn't stop, investment might stop."

News Article | October 12, 2000

Industry leaders say the sell-off in tech stocks has forced many of them to overhaul their tactical -- and even strategic -- planning in response to heightened pressure on many startups to turn a profit sooner, rather than later. In other words, kiss any lingering pipe dreams of instant riches a fond farewell. But most are taking it in stride, writing the buffeting off to the natural ebb and flow that naturally accompanies involvement in high-risk ventures. "Tech is volatile, and people are rediscovering that fact," said Alexandre Alfonsi, the chief financial officer of Nfactory, a Paris-based aggregator of European content. Of course, this summer -- and now autumn -- of tech investors' discontent has made Alfonsi's job that much more interesting. He and executives of more than 100 other startups from Europe and North America now find themselves on the receiving end of tough questioning from venture capitalists, bankers, and prospective partners -- who are all taking extra pains not to get burnt again. After the excesses of last year -- when companies with questionable business models often soared in value after going public -- Alfonsi says there was bound to be a reaction to the "craziness". Still, he added, "I don't believe it's more than a major market correction." That promises to be a major subject of conversation during the course of a three-day conference here sponsored by Dasar. To be sure, there are Kafka-esque tales about the fickle reactions of the princes of high finance to current events. Consider the example of Morten Rynning, managing director of a Norwegian Internet software company, who ran into a brick wall when he sought out venture capital funding earlier this year. "They are like sheep. I spoke with one VC who didn't want to talk unless the company was doing B2C [business-to-consumer]," he said. "That was in February. In April, he was telling us that we needed to become a B2B [business-to-business] firm. "If you're changing that quickly, how can you talk about making three-year investment decisions? They are making it hard, and we're getting hurt by their bad choices." Tech stocks have lost anywhere from 25 percent to 75 percent of their value this year, the sharp declines beginning in March. Yet while it remains a matter of debate whether the worst is over or there's still more carnage to come, Yoav Chelouche, the chief executive of Israel-based Scitex, says there's a silver lining in the current clouds. "What it does is signal a back-to-basics emphasis," Chelouche said. "It means that more than before [the stock sell-off] companies need to focus on putting together a strong management team first. And it means they need to be paying more attention to revenue and profitability than before." But it also means a lot of good companies are in danger of getting lumped together with the non-performers, especially when it comes to the IPO market. Since the tech sell-off, tech IPOs have crumbled., for example, which went public at $11, is currently selling for 63 cents and change. Last week, Scitex was forced to delay a planned public offering of a company spinoff, in part because of the continuing declines in tech stocks -- and this despite a four-year, 60 percent annual growth rate by the unit. See ZDII for US tech investor news. See techTrader for more technology investment news, plus quotes and research. Lots of hopeless Internet startups have been funded by hapless venture capitalists in the last few years. The truth is -- Charles Cooper says -- we've arrived at a punishing phase of the Internet revolution where profits and strong revenue growth suddenly matter. Go to AnchorDesk UK for the news comment. To have your say online click on the button and go to the ZDNet News forum. Let the editors know what you think in the Mailroom. And read what others have said.

Loading Scitex collaborators
Loading Scitex collaborators